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Abstract
Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune
responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR
include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary
emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as
demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including
immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and
chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell
biologic process, whose deviations from normality determine the rules of engagement with the host’s response,
the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including,
immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics
to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San
Francisco on May 14–15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to
CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by
forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop
was a first step toward a second meeting where the focus would be to address the actionability of some of the
questions identified by working groups. In this event, five working groups aimed at defining a path to test
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hypotheses according to their relevance to human cancer and identifying experimental models closest to human
biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to
CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best
represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions
from each group and should be considered as a first milestone in the path toward a more contemporary
understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects
related to CIR such as the microbiome, the individual’s recombined T cell and B cell receptors, and the metabolic
status of cancer and immune cells were not fully included. These and other important factors will be included in
future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to
answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held
in Houston on September 4–5, 2019.
Keywords: Cancer immune responsiveness (CIR), Immune checkpoint inhibitor (ICI), Immune oncology (IO),
Immunotherapy, Tumor microenvironment (TME), Tumor mutational burden (TMB), Immunogenic cell death (ICD),
Biomarker, Germline molecular alterations, Somatic molecular alterations, Cancer immune phenotype
Background
Tumor immunotherapy has changed the therapeutic
landscape for patients with cancer. While several classes
of drugs are demonstrating clinical benefit, immune
checkpoint inhibitor (ICI) therapy in particular has re-
ceived considerable attention because these agents im-
prove overall survival and are effective in a wide range
of tumor types [1, 2]. Why some patients respond ini-
tially to ICI therapy and not other immuno-oncology
(IO) regimens is not clearly understood. Indeed, many
cancer patients do not benefit from IO treatments even
when the tumors display favorable immune characteris-
tics [3] and the reason(s) for their resistance to these ap-
proaches remain(s) uncertain. To date, established
experimental systems have been flawed in answering this
critical question because they cannot adequately repli-
cate the complicated evolutionary processes inherently
impacting human cancers in immune competent hosts.
While current models are useful for hypothesis gener-
ation, they need to be realigned and reinterpreted within
the framework of human biology. Thus, a cohesive blue-
print is needed to generate definitive information rele-
vant to human cancer. This is why the Society for
Immunotherapy of Cancer (SITC) organized a Task Force
on Cancer Immune Responsiveness (CIR) to stimulate in-
teractions among multiple disciplines and outline salient
open questions and define new priorities for research in
tumor immunology and immunotherapy [4].
The taskforce was launched by a workshop held in San
Francisco on May 14–15, 2018 that convened immunolo-
gists, geneticists, cell biologists, molecular biologists, bio-
physicists, computational analysts and oncologists, and
aimed at two preeminent goals: 1) to identify the funda-
mental questions related to CIR and 2) to create an inter-
active community of experts that could guide scientific
and research priorities by forming a logical progression
supported by multiple perspectives to answer the funda-
mental questions and uncover mechanisms of CIR.
Diverse and often divergent observational or experi-
mental justifications for immune resistance have been
described [5, 6]. Indeed cancers can be conceptually dis-
tinguished into immune “active” versus immune “silent”
tumors according to the transcriptional expression of a
set of genes termed the immunologic constant of rejec-
tion (ICR) [7, 8] that defines the continuum of cancer
immune surveillance within the tumor microenviron-
ment (TME) [9]. Galon et al. have shown that the
immune active or immune silent tumors associated with
cytotoxic and memory T-cells, Th1 cells, and
interferon-gamma (IFN-γ) signature are correlated with
long-term survival or rapid recurrence respectively [10,
11]. The consensus Immunoscore categorizing inflamed
and non-inflamed tumors was recently validated globally
with profound clinical implications [12]. For instance,
the characterization of primary colon cancer immune in-
filtrates by the Immunoscore could refine and extend
the proportion of Stage IV patients eligible for immune
checkpoint inhibitors treatment, as suggested by Le
et al. [13, 14]. Furthermore, the Immunoscore was able
to identify good prognostic colon cancer Stage II
patients with high-risk clinico-pathological features for
whom adjuvant treatment may be avoided, underlying
once more its clinical utility [15]. In locally advanced
Stage III colon cancer, risk assessment and more precise
risk categories should be used to inform the duration of
adjuvant chemotherapy. The consensus Immunoscore
stratifying patients with stage III colon cancer could help
aid in clinical decision-making, in particular the possibil-
ity to decrease un-necessary chemotherapy regimen
within high Immunoscore patients [12, 16–18].
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The 4-category classification of tumors (immune hot,
altered-immunosuppressed, altered-excluded, and cold)
based on their immune infiltrates and Immunoscore
proposed in 2009 [11] could prove instrumental in guid-
ing the most appropriate therapeutic approach [19].
Ayers et al. [3] have categorized tumor types according
to an analytically and clinically validated IFN-γ-related
gene signature termed the tumor inflammation signature
(TIS) that largely overlaps with the ICR and importantly
is predictive of clinical benefit of ICI therapy. Other sig-
natures outlining the central role that IFN-γ signaling
plays in determining the immune landscape of cancer
and its responsiveness to immunotherapy agents have
been described [6, 9, 20–22]. Of note, as recently re-
ported by Cristescu et al. shown in The Cancer Genome
Atlas (TCGA) dataset, a strong correlation (r > 0.9) be-
tween several other previously published transcriptional
signatures reflective of the T cell-inflamed TME associ-
ated with cytolytic processes was demonstrated [23].
A set of about one thousand breast cancers from
TCGA is subdivided into separate immune phenotypes
called ICR-1 to ICR-4 according to the incremental level
of expression of ICR genes. The expression of transcrip-
tional signatures associated with immune regulatory
properties is then considered for their presence in each
immune phenotype [6]. The transcriptional signatures
are representative of distinct immune regulatory mecha-
nisms including the immune checkpoint cluster [24],
regulatory T cells [25], IL-23/IL-17 axis [26], myeloid
suppressor cells [27], IDO [28], immunogenic cell death
(ICD) [29], TAM tyrosine kinase receptors [30], hypoxia
[31], cancer-associated fibroblasts [32] and barrier mole-
cules [33]. Self-organizing clustering distributes signa-
tures according to the immune landscapes pre-defined
by the ICR signature and demonstrates that most
immune regulatory functions pertain to immune active
cancers (ICR-4) [6]. Most recently, it has been reported
that tumors with a high glycolytic rate are resistant to
adoptive cellular therapy (ACT) suggesting that modula-
tion of metabolic pathways may also affect immune cell
function [34]. It has also been shown in humans that
TME with increased metabolism (not necessarily and
only associated with increased glycolysis) are resistant to
immune checkpoint blockade including programmed cell
death protein 1 (PD-1) blockade [35, 36]. However, the
actual rate and frequency of metabolic alterations
either related to intrinsic immune cell function or re-
active to hypoxic conditions in different cancer types
are currently unknown.
Enrichment of immune regulatory functions within
the active immune landscapes [6] suggests that resist-
ance to ICI therapy is due to the co-existence of alter-
nate regulatory mechanisms that overrule a single
blockade. We refer to this mechanism as adaptive
immune resistance and propose that the cancer immun-
ity cycle described by Chen and Mellman [37] pertains
particularly, and perhaps exclusively, to this context.
Conversely, immune silent cancers are unlikely to re-
spond to ICI therapy because checkpoints are irrelevant
to their evolution (primary immune resistance). In
addition, immune responsive tumors may become resist-
ant under the selective pressure induced by therapy by
developing escape mechanisms (acquired immune resist-
ance). Finally, a non-biological type of resistance to ther-
apy (pseudo immune resistance) should be specified that
it occurs when a given treatment is terminated prema-
turely in order to limit toxicity. Similarly, other external
factors may be at the basis of lack of response that are
beyond the biology of individual tumors such as varia-
tions in product quality in the case of ACT [38] or in
cases of immunodeficiency in which patients seem un-
able to mount an effective immune response, despite
having favorable predictors at the tumor site [39].
Immune active cancers display a distinct genetic pro-
file characterized by a high mutational burden [40, 41].
This association is commonly attributed to increased
stochastic chances of expressing neo-epitopes that
stimulate adaptive nonself-recognition [42, 43]. In im-
mune active cancers, enriched mutations affect the func-
tion of cancer driver genes, leading to the hypothesis
that cancer evolution in the immune-competent host
faces a stochastic binary choice: some cancers accrue an
orderly succession of genetic alterations that engender
essential growth advantages in strict avoidance of add-
itional unnecessary functions; this process may be com-
pared to the assembly of normal tissues orchestrated by
differentiating stem cells during development [44]. The
mutational profile characteristic of immunogenic tumors
is in contrast with the higher frequency of copy number
alterations observed in immune silent tumors. In this
case, an inverse correlation with immune signatures or
immune infiltration has been observed [45, 46]. As soon
as deviations occur from this orderly process and cancer
growth becomes dependent predominantly on genetic
instability, a “trial-and-error” reshuffling of genetic traits
selects for a proliferative advantage over normal cell
growth. Pediatric tumors arise with primary genetic in-
stability and most adult tumors with secondary genetic
instability associated with prolonged stress and inflam-
mation. The intrinsic biology of the cancer cell primarily
orchestrates its surroundings [47] by releasing factors
that stimulate stromal and vascular architecture in the
developing new tissue as per Virchow’s “healing wound”
model [7, 48]. The cross-talk with cells may result in
chemo-attraction of innate and adaptive immune cells
turning cancer into a chronically inflamed tissue [48].
This disorderly process, however, appends the stochastic
risk of gradually accumulating unnecessary functions
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such as chemo-attraction that may trigger immune
recognition [48]. In addition, it is possible that genetic
instability may result in a disorderly cell cycle prone to
ICD [49]. Indeed, the expression of the ICD signature is
tightly associated with the immune active landscape [6, 50]
characterized in turn by genetic instability [51]. Thus, the
destabilization of the cellular life cycle resulting in ICD
may represent the primary trigger of immunogenic
reactions in line with Polly Matzinger’s danger model [52]
associated with release of damage associated molecular
pattern (DAMP) [53, 54].
CIR is determined by the summative effects of the
genetic background of the host, somatic alterations
related to the oncogenic process, and environmental
modifiers [55]. This synopsis will present various views
on how these determinants may affect immune respon-
siveness and offer an integrated and sequential view. We
appreciate that this first effort is far from comprehensive
and that other relevant aspects related to immune
responsiveness such as the microbiome and the meta-
bolic status of cancer and immune cells are not included
in our initial assessment. These and other important fac-
tors as well as addressing the relevant questions from
each working group will be included in future activities
and meetings of the taskforce.
Germline genetic contributions to CIR
Growing evidence suggests that the host immunity is in-
fluenced by inherited factors. However, the germline
genetic contribution to CIR has not been systematically
explored due to several hurdles. First, since highly effect-
ive immunotherapeutic approaches such as the ICIs have
been only recently implemented, limited datasets are
preventing conclusive association studies. Second, large
datasets such as TCGA have scant information on clin-
ical outcome, particularly on response to IO agents. In
addition, TCGA collected samples from primary tumors
(with the exception of melanoma) while IO is applied
mostly in metastatic settings. Yet, these datasets are still
useful for assessing the contribution of the genetic back-
ground to the development of anti-tumoral immunity by
matching germline data to the functional orientation of
TME derived from transcriptional data.
Rationale supporting the relevance of germline studies to
CIR
Twin have shown that both heritable and non-heritable
factors significantly contribute to an observed phenotype
[56–58]. These findings might have important implica-
tions for CIR as divergent baseline conditions might
reflect a different predisposition to mount an adequate
immune response after a certain stimulus.
Genome-wide association studies (GWAS) have identi-
fied more than three hundred susceptibility loci
predisposing to the development of autoimmune dis-
eases. Moreover, studies of severe autoimmune or im-
munodeficiency syndromes identified several causative
variants [59]. Polymorphisms of Human Leukocyte Anti-
gen (HLA) molecules have been associated with variable
responses to infection, inflammatory conditions, auto-
immune diseases, and development of virus-induced
tumors and some not-known to be virus-induced such
as non-small cell lung cancer [60] and hematological
malignancies [61]. However, GWAS are limited to find-
ing common variants. Whole exome sequencing (WES)
offers complementary information to GWAS on rare
variants in coding regions, and ultimately, whole genome
sequencing (WGS) can systematically assess common
and rare variants, as well as structural variation.
As compared to common risk polymorphisms, which
are mostly localized in non-coding regions, rare protein-
coding variants are more likely to lead to a loss or
altered function of the protein [59] that may influence
treatment outcome in patients who do not demonstrate
otherwise signs of immune dysfunction(s). This strategy
also might be explored to gain mechanistic insights
about severe immune-related adverse events. It is pos-
sible that the germline control of host immunity is not
subjected to the selection pressure relevant to the gen-
eral population in relation to infectious challenges. In
contrast to GWAS designs of disease risk, which yielded
only the low-penetrant risk effect associated with tested
common genetic variants, these effects may be substan-
tially enhanced in the context of immunotherapy treat-
ments. Thus, minor alleles of common variants may be
comparably distributed in the population but under
iatrogenic immune stimulation their effect on cancer re-
sponsiveness can become noticeable. Therefore, empir-
ical validation of the contribution of common variants
to CIR will be needed as part of larger genome-wide
scans, including IO-based GWAS. For example, a recent
study of melanoma showed that the functionally relevant
common single nucleotide polymorphisms in interleukin
pathways may associate with improved melanoma survival
independent of the other prognostic predictors [62].
Potential mechanisms implicated in germline immune
modulation
Germline genetic factors might influence CIR in myriad
ways [63–67]. Some examples are shown in Fig. 1. In
addition to variants of immune-related genes, mutations
of DNA-repair genes can cause accumulation of somatic
alterations by increasing genomic instability, which in
turn might facilitate the development of neoepitope-
mediated tumor rejection. It is likely that high tumor
mutational burden (TMB) contributes to responsiveness
to ICIs in patients with germline mutations of
mismatch-repair. Would patients carrying such
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mutations be also more likely to develop acquired, immune
resistance? The influence of germline variants on
cancer-cell’s intrinsic features to modulate anti-tumor im-
mune response needs to be addressed by germline-somatic
integrative analyses through whole-exome/whole-genome
sequencing [68] paired with clinical outcome information.
Mixed responses are common in ICI-treated patients and
are largely attributed to somatic tumor genomic heterogen-
eity [69]. Can the germline genetic background modify the
degree of tumor immune heterogeneity and therefore the
likelihood to develop mixed responses?
Evidence supporting the existence of a link between
germline variants and CIR and clinical implications
Few studies have investigated the germline contributions
to CIR. In metastatic melanoma, the link between
polymorphisms of genes implicated in the pathogenesis
of autoimmune diseases, such as C-C motif chemokine
receptor (CCR)-5 and IFN regulatory factor-5 and re-
sponsiveness to chemo-immunotherapy [70] or adoptive
therapies [71, 72], was reported. Several studies indicated
that CTLA-4 polymorphisms affect response to CTLA-4
blockade [73–75]. In all cases, the reports are inconclu-
sive since these studies lacked adequate validation. A
tenuous or lack of associations between HLA polymor-
phisms and responsiveness to the systemic administra-
tion of interleukin (IL)-2 in metastatic melanoma was
reported by early studies [76], while a modest, yet sig-
nificant, association between HLA variants and survival
was detected in melanoma patients treated in adjuvant
settings with IFN-α [77]. A recent study testing the
effect of immunomodulatory expression quantitative
Fig. 1 Germline contributions to CIR. Germline genetic contributions to CIR. Genetic germline variants can influence CIR in different ways, which
are tightly interconnected. Variants associated with attitude to smoke or mutation in DNA-repair genes (e.g., DNA mismatch repair genes) can
cause the accumulation of somatic alterations which in turn might facilitate the parallel development of neoepitope-mediated immune
recognition.. Polymorphisms of genes that modulate critical immunologic pathways such as IFN signaling and differentiation and function of T
cells and B cells might influence the development of tolerant vs cytotoxic TME. The same could be said of variants in genes governing antigen
presentation such as HLA class I and II, ICD, innate-immunity function in macrophages, natural killer (NK) cells, and granulocytes. Polymorphisms
of TLR4, P2RX7, and FPR1 have been associated with differential outcome in breast and colon cancer patients treated with adjuvant
chemotherapy, likely through the modulation of ICD-mediated anti-tumor immune response [63, 64]. HLA-E, a non-classical HLA molecule, is
recognized by specific NK cell lectin-type receptors with either activating or inhibiting activity in the context of specific and redundant antigenic
presentation. HLA-E polymorphisms might have an impact on anti-tumor response independently from the CIR mechanisms recognized so far
[65]. Variants in genes encoding for chemokines or chemokine receptors might also differentially modulate intra-tumoral recruitment of immune
cells. Variations in protein-coding regions of genes affecting structure or expression of molecules targeted by IO agents might influence their
efficacy. Polymorphisms of crystallizable fragment (Fc)-γ receptor genes have been associated, although inconsistently, with distinct outcomes in
patients treated with Rituximab and Trastuzumab [66]. Such variations might potentially influence the efficacy ICIs via antibody-dependent
cytotoxicity (ADCC) lysis of target or tumor cells [67]
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trait loci (eQTLs) identified an association between
eQTL in IL-10/BATF3 locus on 1q32 and survival in
melanoma, complementing other established clinico-
pathological prognostic markers [62]. Interestingly, the
associated eQTL is a proxy of variants associated with
multiple autoimmune conditions [78], suggesting that
propensity to autoimmunity provides survival advantage
in immunogenic tumors.
Recently, large genetic study on melanoma and lung
cancer patients treated with ICIs has shown that a low
level of germline HLA-I heterozygosity is strongly asso-
ciated with poor outcomes [79]. This effect is enhanced
by, but is not dependent on TMB. Furthermore, efficacy
of ICI was diminished by somatic loss of HLA-I hetero-
zygosity by the tumor cells. Molecular dynamics simula-
tions of HLA super-types associated with poor prognosis
revealed distinctive elements that might affect neoanti-
gen recognition by cytotoxic T cells [79]. Preliminary
studies in melanoma patients employing WES and geno-
typing suggest that genetic variants in interleukin- and
chemokine-related pathways are associated with differ-
ential responsiveness and toxicity across anti-PD-1 and
anti-CTLA-4 treatments [80]. Also, germline mutations
disrupting miRNA regulatory pathways have been linked
to toxicity and responsiveness to PD-1 blockade [81].
Interestingly, recent data suggests that polymorphisms
of Fc-γ receptor influence the efficacy of anti-CTLA-4
treatment, and the modulation seems to be relevant only
in the context immunologically active tumors [67]. Pre-
liminary data generated by the analysis of TCGA sam-
ples suggests that a proportion of transcriptional
signatures related to leukocyte abundance and functional
orientation in the TME is partially heritable (E. Ziv, this
workshop). In addition, the expression of several
immune-related genes and immune-related signatures
have been recently associated with different germline
variants [82].
The identification of common genetic variants asso-
ciated with treatment outcome might lead to the
development of better patient stratification. If such
variants are identified, polygenic scores might be used
to define predictive classifiers. While it is unlikely that
germline variants can be used as a single marker for
stratification purposes in metastatic patients, they can
be integrated with other biomarkers (such as muta-
tional load, presence of somatic mutations, or tran-
scriptional and morphologic features) to develop
multi-factorial predictors. In the adjuvant setting,
germline variants associated with toxicity can guide
the selection of patients for the modest survival bene-
fit. Additionally, germline testing may inform the
assessment of therapeutic index for administering im-
munotherapies in patients with pre-existing auto-
immune diseases.
Germline investigations might also have profound im-
plications for therapeutic interventions. For example, the
observation that specific HLA-I super types are associ-
ated with increased immune responsiveness [79] offers
the opportunity to develop specific vaccination strategies
targeting immune dominant, super type-restricted
neoantigens. Similarly, the associations of eQTLs in
IL-10 locus with melanoma progression [62] may expand
the applicability to immunotherapy with the concurrent
targeting of IL-10 receptor during the treatment with
ICI [83, 84]. It will be critical to understand how muta-
tional signatures across cancer types and the HLA-I
genotype of patients interact to impact the repertoire of
neoepitopes presented by tumor cells, and affect
lymphocyte density, immune contexture, CIR and ultim-
ately clinical outcome.
Controversies
While genetic studies may be helpful, each approach
has significant limitations. GWAS studies are limited to
identifying common variants which are either directly
genotyped on an array or, more commonly, imputed.
Although GWAS have identified a large number of loci
associated with autoimmune disorders and other com-
plex traits, for most complex phenotypes, discovered
loci accounted for a relatively small fraction of the her-
itability of the phenotype. The effect sizes of the vast
majority of these variants are small, with the vast ma-
jority of these odds ratios being 1.2 or less [85], with
few notable exceptions showing the stronger effect size
with meaningful utility, such as HLA effects on auto-
immunity [86]. As individual markers, these variants
provide limited clinical utility. However, if enough can
be combined (e.g. by computing polygenic scores), they
may become useful [87].
GWAS in the context of immunotherapy, as men-
tioned earlier, may not follow the pattern of expected
low-penetrant risk effects in disease risk. Thus, it is pos-
sible that IO GWAS will identify genetic loci with stron-
ger risk effects and clinical applicability, as suggested by
recent pharmacogenomics associations [62, 88]. Import-
antly, the clinical risk effects of germline variations by
GWAS can be enhanced by the combined testing of
common and rare variation, further improving their pre-
dictive capacity [87]. While next-generation sequencing
(NGS) offers notable advantages, there are also limita-
tions: WES, as cost-efficient alternative mapping germ-
line variations in coding regions, targets only ~ 1–2% of
the genome. Nevertheless, a focused application of WES
and targeted panels is widely used in screening of germ-
line mismatch repair mutations as predictive surrogates
of outcomes to PD-1 inhibitors in colon cancer [89] and
other tumor types [90]. WGS provides the most compre-
hensive platform for germline screening in IO and CIR.
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However, due to the complexity of the data analysis,
complementing approaches are needed, including the
combined analysis of common and rare variation in
gene-burden tests integrated with other layers of bio-
logical information, to aid in prioritization of non-
coding but functionally-relevant germline markers.
Take-home messages and challenges for germline genetic
contributions to CIR
 Recent findings suggest that germline variants might
shape intra-tumoral immune response, and influence
responsiveness and toxicity to immunotherapy.
 Current large cancer databases are useful resources
to explore the relationship between individuals’
genetic background and intra-tumoral immune
response but lack information on treatment
outcome, especially on immunotherapeutic agents.
 The constitution of appropriate databases paired
with high-powered studies are needed to define the
magnitude of genetic germline contributions to CIR
and to identify putative germline genetic immune
biomarkers.
 It is critical to establish dedicated large collaborative
consortia or networks collecting harmonized clinico-
pathological information, which represents a major
roadblock in the systematic exploration of the
germline component in IO.
 Germline information should be integrated with
phenotypic information such as somatic alterations,
epigenetic and transcriptional features to increase
prediction accuracy.
 Analytic integrative pipelines need to be
implemented for deciphering causal associations and
for prioritizing putative functional variants and
pathways.
 Once identified, genetic germline biomarkers might
be used to increase treatment outcome, adverse
event prediction and to define novel therapeutic
strategies.
Unanswered questions for germline genetic contributions
to CIR and strategies to meet the challenges
 Which are the key molecular mechanisms involved
in anti-tumor immunity that might be modulated by
germline genetic variants?
 Are common genetic polymorphisms associated
with a differential spontaneous or treatment-induced
anti-tumor immune response?
 How can we implement the study of host genetic
diversity to identify novel biomarkers of
responsiveness or toxicity to cancer
immunotherapy?
Large cooperative clinical trial groups might be best
poised to accrue the necessary extremely large sample
size. Thus, it is difficult to implement this approach in
the therapeutic setting. As large sample sizes are needed
for germline studies, the taskforce members agree that it
is critical to establish collaborative networks dedicated to
these investigations, which will allow harmonized collec-
tion of clinic-pathological information. Collaborations
might occur by sharing patient samples and/or data. The
cohorts could be enriched for exceptional responders,
rapid “progressors”, or for patients experiencing severe
adverse events. Collection of germline DNA should be
included in clinical trials. Ethical and regulatory issues
might represent an obstacle for sharing germline data
and need to be prospectively taken into account at the
time of study design. Funding agencies are often requir-
ing to deposit in publicly accessible repositories germline
and phenotypic information generated by the awarded
researches, and therefore it is expected that amount of
germline data for CIR exploration will increase in the
next few years. National large-scale initiatives, e.g. the
UK Biobank, might represent additional resources for
this kind of exploration. Going forward, it would be crit-
ical to integrate germline data with phenotypic attri-
butes, such as transcriptomic signatures, epigenetic, and
somatic alterations to increase CIR prediction accuracy
[91]. It is possible that the effect of some germline poly-
morphisms is restricted to certain cancer immune phe-
notypes, therefore increasing the complexity of the
analytic approach [67].
To properly address the germline questions, it will be
important to standardize platforms and methodological
approaches. The implementation of bioinformatics pipe-
lines, such as fine mapping strategies to prioritize puta-
tive functional variants and to identify true causal
associations, will be critical [92, 93]. Direct genome-
editing techniques, e.g. CRISPR/Cas9 and in vivo model
for studying CIR, will offer the opportunity to translate
association-study based information into biological rele-
vant knowledge [93].
Somatic genetic contributions to CIR
The accumulation of different genetic and epigenetic al-
terations are the origin of inter- and intra-tumor hetero-
geneity impacting cancer pathways, driving phenotypic
variation, and posing significant challenges to personal-
ized cancer medicine [47, 94, 95]. Beyond these effects,
an open question in IO is whether and how tumor in-
trinsic features affect the characteristic of the TME. The
need to address this question arises from improvements,
in terms of clinical outcomes, to therapeutic approaches
targeting immune cells especially in melanoma and lung
cancer but also other cancers [90, 96]. Our poor under-
standing of the genetic mechanism contributing to the
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host-tumor interaction limits further development of
more effective treatments. Many sources of evidence
have recently shown that tumor cell-intrinsic signaling
pathways and gene regulatory networks play a funda-
mental role in the degree of T cell infiltration [8, 97, 98].
However, the understanding of the complexity of the
tumor-host interaction also requires taking into account
the specific genetic makeup of the host (patient geno-
types) [99] and interaction with the environment [99,
100]. In addition, mutations driven by immunologic se-
lection have been described such as alterations in JAK
[101] and IFNGR [102] genes. While knowledge about
the somatic genetic contributions to the determination
of immune responsiveness remains limited, future at-
tempts aimed at addressing the above questions should
utilize advanced system genetic approaches leveraging
the availability of multi-omics, large-scale datasets [103].
Predictive biomarkers of ICI therapy
The most pressing clinical question for ICI therapy is
what are the predictive biomarker(s) of response and
resistance to ICI therapy? Identification of such predict-
ive biomarker(s) would improve patient selection, limit
toxicity (including financial toxicity), and guide
biology-based combinations thus moving the immuno-
therapy field towards personalized medicine [104]. In
order to identify these predictive biomarkers, under-
standing genomic characteristics underpinning tumor
immunogenicity is essential as it would enable deeper
comprehension of tumor intrinsic mechanisms of
primary resistance to ICI therapy (which is applicable to
majority of patients treated with ICI therapy) and those
mechanisms governing acquired resistance.
This critical question is currently under intense inves-
tigation. Accumulating evidence supports the existence
of tumor intrinsic features such as TMB, correlated to
an immune active TME and predictive of response to
PD-1/PD-L1 blockade, independent of PD-L1 expression
[40, 90, 105]. The use of TMB as a clinical predictive
biomarker poses, however, some challenges in terms of
harmonization and standardization. For example, the use
of NGS panels needs the selection of suitable TMB cut-
offs. Moreover, the selection of such cutoffs should take
into account predictive power and specificity within dif-
ferent tumor indications, sequencing methodologies and
depth of coverage. The assessment of biomarkers corre-
lated to TMB such as genomic alterations in DNA dam-
age response (DDR) genes has also been recently
suggested [106]. Indeed, alterations in DDR pathways
may result in higher TMB and neoantigen load, and
could potentially be a more accurate predictive marker
to identify ICI therapy responders. Yet, it is not clear if
all DDR pathway alterations will impart increased tumor
immunogenicity, and additional work is required to
understand what is the impact of co-DDR pathway alter-
ations on clinical outcomes to ICI therapy [107]. This
understanding would improve patient selection strategy
as well as identify ICI therapy combination therapies
that may exploit these tumor-intrinsic characteristics. In
addition, blood-based genomic assays with cell free DNA
(cfDNA) or circulating tumor cells (CTC) assessing DDR
genes as a surrogate to estimating TMB could result in a
potential solution to limitations of tissue availability.
Associations between somatic alteration and features of
TME
Recent observations have demonstrated that specific
somatic alterations in tumor cells correlate with
changes in the TME, including overall lymphocytic
content, cellular composition, and intracellular signal-
ing [47, 108]. In some cases, functional interactions
mediating these associations have been established. As
highlighted previously, correlations are seen with the
overall extent of DNA alterations, both mutation and
copy-number alteration burden, but somatic alteration
in individual proteins or pathways also impacts the
TME. For example, somatic mutations that lead to
tumor-intrinsic β-catenin activation have been identi-
fied as mediating exclusion of T cells from the TME
[108]. In prostate cancer, KRASG12D mutations lead to
increased production and secretion of granulocyte-ma-
crophage colony-stimulating factor (GM-CSF) and
accumulation of immunosuppressive myeloid cells,
suppressing cytotoxic lymphocytes [109]. In glioma,
isocitrate dehydrogenase 1 (IDH1) mutations are
associated with variations in the degree of leukocyte
infiltrate, macrophage content, and repression of
tumor-associated immune responses [110]. Analysis of
cancer genomics has yielded a wealth of associations
between somatic alterations and immune response, in-
cluding with TME composition and response to ICI
therapy [103, 111]. In addition, several computational
studies have demonstrated strong associations
between the genetic makeup of tumors and their im-
mune contexture. By mining large scale datasets, they
revealed that expression of genes associated with cyto-
toxic immune activation was correlated with specific
mutations such as in PIK3CA or MET. However, many
open questions exist on the mechanisms by which
cancer-intrinsic properties affect the heterogeneity of
their immune landscape, and the interrogation of the
spatiotemporal regulation of the immune microenvir-
onment requires novel in vivo genetic experimental
platforms able to model concurrently the heterogen-
eity of the cancer cell and their crosstalk with the
immune microenvironment [98].
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Associations of epigenomic alterations to the features of
TME
The chromatin provides the physical substrate where
epigenetic mechanisms and signaling pathways converge
to coordinate transcriptional programs, playing a critical
role in cellular phenotype and cellular memory. The
chromatin also plays an essential role to repress trans-
posable elements. During cancer development, the
global chromatin landscape in cancer cells becomes
deregulated, as a consequence of altered transcriptional
profiles or mutation in genes encoding chromatin-
remodeling factors, histone modifying enzymes, and
DNA methylation enzymes.
This deregulated chromatin landscape of cancer cells
can play a critical role in the immune landscape and im-
mune responsiveness. As one example, SWI/SNF chro-
matin remodeling complex genes are inactivated
through mutation in ~ 20% of cancers. One subunit of
this complex, PBRM1 is mutated in ~ 40% of patients
with clear cell renal cell cancer (ccRCC). PBRM1 was re-
cently shown to inhibit activation of IFN-stimulated
genes in cancer cells in response to IFN-γ produced by
T cells. Indeed, PBRM1 inactivation increases sensitivity
of cancer cells to T cell-mediated killing and truncating
loss-of-function mutations in PBRM1 is associated with
increased response rates to anti-PD-1 or anti-PD-L1 in
ccRCC patients [112, 113].
Moreover, deregulated chromatin landscape in cancer
cells can be targeted therapeutically to increase immune re-
sponsiveness. For example, DNA demethylating drugs were
previously shown to re-activate human endogenous retro-
virus (HERVs), leading to formation of dsRNA and activa-
tion of pattern recognition receptors, such as the MDA5/
MAVS anti-viral pathway. This leads to a ‘viral mimicry’
state, where cancer cells activate antiviral responses, lead-
ing to immunogenic cell death, Type I and III IFN produc-
tion, and increased antigen processing and presentation
[114, 115]. Recently, reactivation of retroviruses have been
associated with heightened response to checkpoint block-
ade in patients with renal cancer [116, 117].
Finally, besides cancer cell intrinsic chromatin deregu-
lation, immune cells in the TME can also show epigen-
etic alterations. A recent study showed that chronically
stimulated T cells acquire de novo DNA methylation
programs that lock them into an exhausted phenotype.
Moreover, inhibition of DNA methyltransferases can
avoid the onset of exhaustion and increase immune
responsiveness [118]. Altogether, these recent studies
suggest that epigenetic deregulation of cancer cells and
the TME play a key role in the regulation of the immune
landscape and immune responsiveness. Moreover, since
these epigenetic modifications are reversible, they high-
light the potential of epigenetic therapy in improving
responses to immunotherapy.
The following main research questions will be the
focus of the field of immunotherapy of cancer for the
next several years: Can our knowledge of how somatic
alterations influence the TME help us optimize immuno-
therapy combinations? Are there shared themes, across
cancer types, subtypes, or immune response subtypes
[103] that can be exploited for improving therapeutic re-
sponse? How do we harmonize biomarkers derived from
different technologies to best stage a patient for IO
therapy and increase the likelihood of response? Will
understanding the role of epigenetic re-programming
downstream of molecular alterations in tumor cells
reveal new opportunities to combat cancer immune-
evasion strategies?
Take-home messages and challenges for somatic genetic
contributions to CIR
 There are many tumor-intrinsic characteristics that
are invariably correlated to response to ICI and
composition of immune microenvironment.
 Multiple levels of molecular events at genomic,
epi-genomic and regulatory stages can affect the
CIR.
 The uncovering of the casual mechanistic
relationships between genomic and epi-genomic
events and immune composition opens the
possibility to reprogramming the microenvironment
and offers novel therapeutic opportunities.
 How do we deal with the molecular subtypes that
define intrinsic resistance to ICI and expand CIR?
Unanswered questions for somatic genetic contributions
to CIR and strategy to meet the challenges
 Can our knowledge of how cancer-intrinsic features
influence the tumor microenvironment help us
optimize immunotherapy combinations?
 How do we harmonize biomarkers derived from
different technologies in order to specifically tailor
IO therapy for a patient and increase the likelihood
of response?
 Will understanding the role of epigenetic re-
programming downstream of molecular alterations
in tumor cells reveal new opportunities to combat
cancer immune-evasion strategies?
Recognizing that the efforts aimed at addressing som-
atic genetic alterations in cancer are often overlapping
with germline studies for various technical and analytical
reasons, the SITC task force made a decision to combine
the two working groups and align their strategy that has
been described in the previous section, by creating broad
consortia for the accrual, analysis, interpretation and
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validation of identified determinants of CIR. In the up-
coming second workshop on CIR to be held in Houston
in September 2019, we combine de facto the two work-
ing groups and will discuss the pathways for effective
functional integration.
Transcriptional changes related to CIR
CIR can be determined by transcriptional alterations
within the TME, and transcriptional patterns can there-
fore be used to categorize CIR. Early studies using tran-
scriptional profiling suggested a general association
between the presence of activated, tumor-specific CD8+ T
cells and sensitivity to immunotherapy [3, 97, 119–121].
However, with increasing understanding of the complexity
of the TME [122, 123], we need to refine transcriptional
analyses to include not only immune cell-derived tran-
scripts but also transcriptional changes in cancer cells or
stroma cells, which can directly influence anti-tumor im-
mune responses (Fig. 2). The suggestion from the CIR
workshop group focusing on transcriptional alterations
within the TME is to separately define transcriptional
alterations occurring in immune cells, cancer cells, and
stromal cells (non-immune, non-cancer). While sequen-
cing of individual cells would provide more specific
information about individual contributions to the tran-
scriptional activation of a given microenvironment, cells
are generally obtained through tissue separation proce-
dures that disrupt the spatial relationship among cells in
different areas of a given tumor. Therefore, other
technologies should be considered such as quantitative
digital spatial profiling [124] that preserves the spatial
information, contributing to the interpretation of data ob-
tained by cell-restricted analyses.
Immune-related transcriptional alterations
Transcriptional profiling of immune infiltrates is
certainly the most advanced of the these categories with
the majority of the work focusing on signatures associ-
ated with cytotoxic CD8+ T cell activation [3, 20, 122,
123, 125, 126]. However, even for the assessment of
tumor-reactive CD8+ T cells, different groups have used
distinct signatures. Moving forward, it will be critical to
identify the specific set of genes faithfully predicting
intra-tumor CD8+ T cell infiltration and to transcription-
ally define key immune cell types directly involved in the
development/modulation of T cell responses, including
immune potentiating dendritic cells or immune suppres-
sive innate cells (i.e. neutrophils, tumor-associated mac-
rophages). While deriving a consensus transcriptional
signature for CD8+ T cells should be achievable using
currently available data sets, more effort is needed to
comprehensively characterize genes involved in immune
regulation of dendritic cells, macrophages, NK cells, and
neutrophils before specific signatures can be generated.
Advances in single cell genomics now allow paired
analysis of T-cell receptor (TCR) repertoire and tran-
scriptional profiles associated with specific TCR clones
within the TME. Identification of TCR-α and TCR-β
chain pairs in concert with elucidation of neo-antigens
or tumor-associated antigens might allow us to decipher
the immune-dominant T cell responses across multiple
patients, or across different tumors within the same
Fig. 2 The tumor-immune microenvironment consists of a variety of cell types. All cell types comprise different transcriptional profiles. The top
depicts all major categories of cell types present in a TME with a color code indicating their overall predictive value for immune responsiveness
(red more responsive; blue less responsive). Some transcriptional alterations impacting immune responsiveness are highlighted beneath. The
middle depicts a tumor and a subset of immune cells found within a TME and represents the challenge transcriptional profiling is facing right
now. The bottom depicts the ultimate goal – using transcriptional profiling of whole tumor or single cells of the TME to predict
immune responsiveness
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patient. Initial studies in melanoma patients and
melanoma-bearing mice are revealing an association
between relative expansion of certain T cell clones and
responses to immunotherapy [127, 128]. Analysis of the
TCR repertoire of tumor-infiltrating lymphocytes (TIL)
could be paired with longitudinal analysis of blood sam-
ples to elucidate whether tumor-reactive T cells can be
detected in the periphery.
Cancer cell-related transcriptional alterations
Over the last couple of years, an increasing number of
preclinical and clinical studies have provided evidence
that transcriptional alterations within tumor cells can
have a direct impact on the abundance and functionality
of immune cells within the TME [41, 47, 125]. Specific-
ally, activation of certain oncogenic pathways, such as
those controlled by beta-catenin, epidermal growth fac-
tor receptor (EGFR), anaplastic lymphoma kinase (ALK),
and RAS/RAF/MEK as well as expression of mesenchy-
mal transition genes, have been all found to contribute
to immune resistance [41, 125, 129–132]. Interestingly,
co-enrichment of genetic signatures corresponding to
mesenchymal transition, angiogenesis, wound healing,
and hypoxia in baseline tumor samples was found to
identify tumors with innate resistance to anti-PD-1 ther-
apy across different cohorts of patients with metastatic
melanoma [41]. Alterations in transcription are often
mediated by distinct mutations or epigenetic alterations
and would therefore represent defined biomarkers pre-
dicting resistance to currently used immunotherapies
[115, 133, 134]. However, thus far it is unknown whether
these transcriptional alterations are cancer type-specific
or not. Understanding common tumor-intrinsic features
inhibiting anti-tumor immunity across cancers might be
informative for the identification of broadly applicable
tumor cell-intrinsic signatures mediating resistance.
Importantly, these tumor-intrinsic factors can serve as
both predictive and prognostic biomarkers that may im-
prove patient selection, therapeutic decisions, and the
identification of rational co-targets for more effective
immunotherapy-based combinations.
Immune-related cancer cell-intrinsic transcriptional
alterations
Alterations in expression of genes associated with
tumor-immune recognition have been primarily associ-
ated with both innate and acquired resistance to
immunotherapy. These alterations mainly include defi-
ciencies in antigen-presentation machinery and the
IFN-γ response pathway [102, 135–137]. Loss of these
functions are generally enriched in tumors characterized
by elevated mutational load and T-cell infiltration, sug-
gesting that this may be the result of an active immune
escape process promoted by ongoing anti-tumor T-cell
responses [20, 138]. Even though alterations in
antigen-presentation machinery and the IFN-γ response
pathway have been identified for the association with re-
sistance to checkpoint blockade [101, 135, 136], it remains
unclear if these alterations develop de novo in response to
immunotherapy or are present at low frequency before
treatment. Should the latter be the case, the development
of more sensitive technologies detecting those alterations
might assist in predicting acquired resistance and allow
for the targeted use of combination therapies.
Stroma-related transcriptional alterations
Similar to cancer cell-intrinsic alterations, several re-
ports suggested that fibroblasts within the TME can
interfere with anti-tumor immune responses [32, 139].
As the non-immune stroma compartment within the
TME is the least-defined non-cancer compartment, tran-
scriptional profiling should first focus on its precise
characterization before engaging in mechanistic studies.
Besides refining stroma-related signatures, there is an
unmet need to pair analysis of stroma transcriptional
changes with immunohistochemistry or multiplex im-
munofluorescent staining. This integrated analysis would
empower conclusions drawn from transcriptional ana-
lyses and would further increase its ultimate predictive
value. To complete this integrative approach, a major
undertaking to generate databases is needed to correlate
the transcriptional profiles (and other patient specific in-
formation) with clinical response to immunotherapy in-
cluding immune-checkpoint blockade.
Efforts to obtain a comprehensive understanding of
the transcriptional profiles defining T cell-inflamed and
non-inflamed TMEs and their clinical impact are further
hampered by the current imprecise criteria to assess
clinical responses to immunotherapy. Commonly used
clinical criteria, overall survival and progression free sur-
vival, do not always capture the true nature of response
at the level of the single tumor lesion. For example,
while most tumor lesions in a patient might be success-
fully eliminated by the immunotherapeutic treatment,
one individual lesion might progress. This isolated pro-
gression event would mark this patient as “resistant” to
immunotherapy per response criteria but might confuse
the interpretation of the underlying biology. Likely, these
mixed responses represent two different biological phe-
nomena of immune responsiveness: 1) the cancer may
be intrinsically responsive to immunotherapy and 2) in-
dividual lesions may have developed escape mechanisms
(acquired immune deficiency) that allows their isolated
growth. Thus, mixed responses and related survival
should be categorized separately as biologically closer to
acquired immune resistance than other forms of lack of
response that denote a non-responsiveness to the first
therapy, such as primary, compensatory, and pseudo
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immune-resistance. Probably, it would be better to con-
sider long-term progression-free survival and long-term
overall survival, or other clinical endpoints. These
parameters are less affected by conditions, which can in-
fluence the median value [140]. If the transcriptionally
profiled biopsies were taken from a lesion that regressed,
the analysis would correctly predict response to
immunotherapy [141].
More accurate clinical assessment could significantly
improve the research efforts to reveal transcriptional
profiles associated with response or resistance by track-
ing the evolution of the biopsied lesions following im-
munotherapy, rather than the overall health of the
patient. Likewise, a tremendous amount of information
could be gained if multiple lesions within the same
patients could be analyzed in order to concurrently elim-
inate any local or intra-patient factors impacting on
anti-tumor immunity [141]. Contrasting the signature of
progressing lesions to responding lesions from the same
individual patients who clinically benefit from the
immunotherapy may characterize their intra-tumoral
heterogeneity. At best, these analyses should be done
using longitudinal profiling to gain information on
alterations occurring over time in response to immuno-
therapy. Additionally, these longitudinal analyses of indi-
vidual lesions would be extremely useful for clarifying
the transcriptional profiles primarily associated with
primary resistance to immunotherapy or acquired resist-
ance following an initial response.
Take-home messages and challenges for transcriptional
changes related to CIR
 Generation of transcriptional immune signature
linked to functional impact of immune cells on the
overall anti-tumor immunity.
 In order to understand the effects of tumor cell-
intrinsic signaling on anti-tumor immunity, generate
methods that allow increased resolution of tumor-
immune interactions.
 Obtain longitudinal insights into how
immunotherapy, and therapy in general, is
impacting immune infiltration and cancer cell
signaling.
Unanswered questions for transcriptional changes related
to CIR and strategy to meet the challenges
 Can we generate transcriptional signature with high
predictive value for a specific tumor-immune
microenvironment?
 Can transcriptional profiling be developed as a
biomarker for the CIR?
 What technological advances do we need to dissect
the tumor-immune microenvironment in space and
time?
As per germline and somatic genetic studies, the suc-
cess of this focused effort by SITC will depend on the
collection and sharing of congregate information that
can integrate genetic with transcriptional, clinical, and
epidemiological data. In addition, other layers of poten-
tially useful information will depend on the integration
of environmental and behavioral information that may
affect individual patients, such as co-morbidities, associ-
ated therapies, dietary habits, microbiome composition
etc. As transcriptional information can most effectively
summarize genetic with functional information, it will
be the primary role of this task force to identify venues
for integration and entice support from different agen-
cies for the accrual and/or access to quality information
that will be queried systematically following hypothesis-
driven path. As described in this section, as much as
complicated that it may appear, cancer immune biology
is starting to demonstrate recognizable patterns and
predictable associations with potential causative implica-
tions. Thus, we predict that more hypothesis validation,
rather than discovery approaches, will help solve the
enigma of CIR.
Immunogenic cell death and CIR
Immunogenic cell death (ICD) is a regulated form of cell
death accompanied by the release of DAMPs that modu-
late the immunogenic potential of dying cells [29, 142].
ICD is defined by its functional consequence – the gen-
eration of protective immunity specific for dying cancer
cells. During early tumor progression, cancers co-exist
in homeostatic balance with the immune response – im-
mune stimulatory and immunosuppressive events permit
limited immune activation but prevent complete elimin-
ation of the tumor. When tumors manifest clinically,
immunosuppression mediated by regulatory T cells and
myeloid-derived suppressor cells allows tumor growth to
outpace immunological control. ICD shifts the immune
balance from suppression to activation and enables a
productive adaptive immune response coupled with
long-lasting immunological memory. Thus, ICD consists
of two main components: 1) tumor cells that die in a
way that promotes immunity, and 2) immune cells
recruited to the TME that respond and generate protect-
ive immunologic memory (summarized in Fig. 3).
Initiation of ICD and effects on immune response
Numerous forms of regulated cell death have the poten-
tial to induce ICD, and each is characterized by unique
spatiotemporal sequences of DAMP release along with
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release of tumor-associated antigens and recruitment of
antigen presenting cells [29, 143]. In contrast to ICD,
tolerogenic cell death (TCD) results in the absence of or
dampening of an immune response associated with cell
death (see Fig. 3). Notably, classical apoptosis does not
induce ICD, favoring rather TCD, although specific vari-
ants of apoptosis as well as other forms of cell death
may promote ICD [144, 145]. Tumor intrinsic factors
shape the threshold for ICD based on relative levels of
various signaling pathways. Similarly, extrinsic factors
(including differences in the TME based on location,
stage, and cellular composition) will shape both the
threshold and type and quality of immune responses to
ICD. Agents, which activate ICD, also affect non-
malignant components of the TME, which may further
shape the subsequent immune response and/or the sen-
sitivity of the tumor to immune effectors.
Therapeutic manipulation of ICD
The mechanism of cell death affects immunogenic
potential by inducing varying patterns of DAMP release,
and efficacy of ICD-inducing therapy is shaped by
factors intrinsic to the cancer cells, the TME, and infil-
trating immune cells. Chemotherapy and targeted ther-
apy may induce variable quality and quantity of ICD
depending on the underlying mechanism of cytotoxicity,
dose of the agent used, and sensitivity of the local host
immune cells to these agents. For many therapies, espe-
cially chemotherapy or radiation, lower doses may in-
duce more potent immune responses than higher doses,
with the added benefit of fewer side effects, by changing
the temporal dynamics of DAMP release and cell death
[146–149]. Oncolytic viruses may overcome a hostile
microenvironment and recruit immune cells by select-
ively killing neoplastic cells and inducing high rates of
Fig. 3 Immunogenic Cell Death (ICD) and Tolerogenic Cell Death (TCD). Immunogenic cell death can be induced by a variety of mechanisms
that are still being defined, including low dose radiation, low dose chemotherapy, oncolytic viruses and others. ICD triggers translocation or
release of DAMP factors from the dying cell in distinct spatiotemporal patterns that shape the subsequent immune response. DAMPs engage
with receptors on antigen presenting cells (APCs) and, in combination with tumor-associated antigens and type I IFN, trigger APC activation,
maturation, and trafficking to draining lymph nodes. This process can be augmented with TLR agonists in some instances. Once in the lymph
node, APCs engage with cognate T cells and drive T cell activation and proliferation. T cells then traffic to the tumor via CXCL9/10/11 gradients
induced by type I IFN signaling in tumor cells, which can result in rapid tumor elimination and generation of long term protective immune
memory. In contrast, TCD including most forms of apoptosis is a non-inflammatory pathway for cell death which is characterized by membrane
blebbing and loss of DAMP secretion, with sequestration of high-mobility group protein 1 (HMGB1) and phosphatidylserine exposure on the cell
surface. Consequently, pro-inflammatory cytokines including IL-1 and TNF are not released to activate endothelium and recruit other T cells.
Ectonucleotidases CD39 and CD73 degrade ICD-associated ATP to adenosine thereby inhibiting T and NK cell responses with expression of the
A2A adenosine receptor (ADORA2A). This mechanism is used by regulatory T cells (Treg) and inhibits T cell effector function. An
immunosuppressive environment characterized by enhanced myeloid derived suppressor cells and regulatory T cells is established while T cells
fail to activate and form a productive immune response
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soluble antigen and DAMP release while triggering type
1 IFN production to activate innate and adaptive im-
mune responses [150]. Autophagy, a cellular response to
stress that causes recycling of internal organelles for en-
ergy, may alter release of DAMPs or other immune
stimulatory molecules and a cell’s sensitivity to subse-
quent cell death, and can impact efficacy of ICD indu-
cing therapeutics. Heightened autophagy can induce
resistance to chemo- and radiotherapy [151], whereas
therapeutics modulating autophagy pathways may com-
bine with immune checkpoint blockade to increase
anti-tumor activity [152].
Monitoring effects of ICD
There are two classical models for measuring ICD in ex-
perimental settings in vivo [153]. In the vaccination
model, a cancer cell line is treated in vitro with a poten-
tially ICD-inducing agent and inoculated into immuno-
competent hosts, followed by a challenge with viable
tumor cells. True ICD will induce protective immunity
and tumors will not form at the challenge site. However,
this model may not be suitable for all forms of ICD due
to spatiotemporal differences in cell death and DAMP
release. The other system for measuring ICD is an
abscopal model where tumors are implanted in vivo into
bilateral flanks, and a potentially ICD-inducing therapy
is delivered to a single tumor site. Elimination of the un-
treated tumor is evidence for the generation of systemic
productive immunity, an effect that has recently been
defined as an ‘anamnestic’ response [154]. However, this
model can only be used to investigate local therapies be-
cause treatment must be restricted to a single tumor.
One of the significant challenges of monitoring ICD
in vivo is the occurrence of efferocytosis, the process
whereby phagocytes quickly remove dead cells and pro-
mote immunosuppression, which makes cell death diffi-
cult to confirm directly [155].
Biomarkers of ICD
To monitor the induction of ICD and its downstream
effects, a robust biomarker strategy must be incorpo-
rated routinely into clinical trials. These biomarkers
should measure the type of cell death, the release of
DAMPs, and the abundance, identity, and location of
immune cells that contribute to a functional adaptive
immune response. Specifically, biomarkers should distin-
guish between bona fide ICD and direct immune modu-
latory effects of the therapeutic drugs by focusing on cell
types that are immediate sensors of DAMPs. As the end
stage of ICD is a protective T cell response, T cell popu-
lations also should be measured to assess success of
these strategies. Proposed clinical biomarkers of ICD in-
clude direct measurements of DAMPs such as HMGB1,
ATP, calreticulin (CALR), type I IFNs, histones, heat
shock proteins (HSPs), markers of immunological fitness
(LDH release, soluble serum markers), and specific im-
mune cell populations (T cell repertoire and phenotype)
or cell surface receptors they express. One promising
biomarker strategy is the systemic immune inflammation
index, which measures ratios of specific immune cell
types (e.g. neutrophils vs. lymphocytes) to monitor shifts
in the balance of immune populations accumulating
within the TME and peripheral circulation [156, 157].
Once biomarkers are identified, they need to be in-
corporated into early and late stage clinical trials to
build a database of ICD in different clinical and
therapeutic settings.
Take-home messages and challenges for the ICD field
 Tumor cell death can be classified as either
immunogenic (eliciting protective immunity) or
tolerogenic (failure to elicit protective immunity).
 Cell death elicited therapeutically can induce the
release of DAMPs which shape the subsequent
immune response.
 ICD is currently measured in model systems via its
functional consequences – protection from tumor
challenge, but robust biomarkers for clinical utility
remain undefined.
To accelerate our understanding of ICD and ability to
manipulate it for clinical benefit, the field needs to:
 Characterize upstream and downstream events that
drive ICD on a genetic, molecular, and cellular level.
 Establish better animal models for ICD assessment
that more closely replicate human tumor immune
biology.
 Develop techniques to measure tumor cell death
and released DAMPs in vivo accurately and
efficiently.
 Improve biomarkers to measure consequences of
ICD including the induction and maintenance of
anti-tumor immunity.
Unanswered questions for the ICD field and strategy to
meet the challenges
 What are the key molecular events that occur
during immunogenic cell death that prime a robust
immune response and promote immunological
memory?
 Which therapeutic strategies will more effectively
promote ICD while minimizing off target inhibition
of immune responses?
 How can detection of immunogenic cell death be
routinely incorporated into clinical trials?
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A clear value of the study of ICD is its relevance to
the determinism of CIR. The value of in vitro ICD stud-
ies is limited because several aspects of the immune
physiology determining CIR can only be study in in vivo
models. Yet, as discussed in the following section, ani-
mal (mouse) models have their own limitations. Thus, a
decision was made by the SITC task force to integrate
the two study groups into one to better define ways to
exploit the induction of DAMPs in the context of ICD
in xenograft models or other tissue modeling substitutes.
This approach will be able to help us understand the
role of different components of innate and adaptive
immunity and how the components are sequentially
involved in the determinism of CIR. Thus, the two
working groups will be combined in the upcoming CIR
workshop with the intent of building hypothesis-driven
models that could address the respective questions and
other related questions, for instance, the requirement of
chemo-attraction and the mechanisms of chemo-
repulsion that may affect migration of adoptively trans-
ferred immune cells. These issues will be the basis of
discussion going forward.
Experimental models of the immune landscape of
Cancer
Despite advances in cancer genomics and cell biology to
aid the rational design of new oncology drug targets, the
rate of translating promising preclinical findings into
successful human clinical trials remains extremely low.
One obvious reason is that animal models of tumors do
not reflect all of the features of genetic heterogeneity,
complex tissue architecture, and immune microenviron-
ment of human cancer. There is an urgent need to de-
velop well-characterized preclinical models to improve
the correlation between preclinical efficacy and clinical
outcomes [158, 159]. To further understand the current
state of the art of this topic, SITC Workshop Session V
provided an overview of mouse models used in cancer
immunology research and drug discovery. Special attention
was focused on humanized mouse models, carcinogen-
induced mouse models, and modeling of the TME.
The advantages and limitations of currently available
humanized mouse models
In past decades, there was significant advancement in
the development of immune-compromised mice, from
athymic nude to Severe Combined Immune-Deficiency
(SCID) to Non-obese-diabetic SCID Gamma (NSG) mur-
ine models [160]. NSG mice demonstrate high engraft-
ment efficiency of human hematopoietic stem cells
(HSC), but success has been limited because of the grad-
ual development of xenogeneic graft-versus-host-disease
(GVHD) [161]. HSC growth and differentiation is also
impaired by lack of the appropriate human cytokine
expression by the host animal [160]. The lack of an
intact lymphoid architecture and adaptive immunity re-
sults in failure to replicate the TME [2]. To highlight ex-
amples of humanized mouse work in immunotherapy
research, a recent study of pembrolizumab efficacy in
triple negative breast cancer patient-derived xenografts
(PDX) in HSC-engrafted NSG mice has shown the simi-
lar response patterns as in patients [162, 163]. While
these studies are promising, there is room for improve-
ment in these models, and the development of next gen-
eration humanized mice to provide preclinical models
for drug development is in progress.
Design of the next generation of humanized mouse
models
The next generation of humanized mouse models has to
focus on ameliorating the deficiencies of current models.
Transgenic expression of human cytokines, HLA mole-
cules, and certain hormones would help this goal. In
addition, knockdown of mouse major histocompatibility
(MHC) Class I and Class II could reduce the severity of
GVHD [164]. One of the major approaches for next gen-
eration humanized mouse development is to express hu-
man cytokines and other genes in the mice, such as
human macrophage colony-stimulating factor (hM-CSF),
hIL-3/hGM-CSF, human signal regulatory protein
(hSIRPA), human thrombopoietin (hTPO), Rag2-deficient,
γ-chain negative (MISTRG), and NSG mice carrying the
transgenes for hstem cell factor, hGM-CSF, and hIL-3
(NSG-SGM3). These new generation mice are engineered
with a CSF-1-dependent and -independent compartment,
enabling the study of the interaction between myeloid
cells, antigen presenting cells, and T cells in the reconsti-
tuted TME [165, 166]. Melanomas implanted in MISTRG
mice have enhanced primary tumor development associ-
ated with increased human macrophage infiltrate, which
has also been demonstrated in human patients.
NSG-SGM3 mice expressing hCSF and hGM-CSF/IL-3
transgenes have shown enhanced frequency of intra-
tumoral regulatory CD4+ T cells [166].
Leveraging carcinogen-induced mouse models to study
sensitivity and resistance to cancer therapies
Despite some encouraging initial responses, ICIs are not
effective in many patients with lung cancer, and acquired
resistance is often implicated in clinical failure [167]. To
study mechanisms of resistance, a carcinogen-induced
squamous lung cancer model originally sensitive to im-
mune checkpoint blockade has been used to mechanis-
tically validate resistance-specific genetic alterations
identified by DNA and RNA sequencing of recurring
tumors from patients after treatment. For instance,
beta-2-microglobulin (B2m) gene loss has been identified
in therapy-resistant tumors [90, 101, 135, 136].
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Knockout of B2m in the carcinogen-induced lung squa-
mous cell line (UN-SCC680AJ) susceptible to PD-1
blockade confers resistance to PD-1 blockade [136].
Such a platform represents a useful system to validate
and test tumor-cell intrinsic factors that contribute to
resistance to immune checkpoint blockade. Since TMB
is positively associated with response to immune check-
point blockade, it is likely that models in which the
tumors have an elevated mutational load (e.g.
carcinogen-induced models) will be valuable for studying
sensitivity and resistance to cancer immunotherapies. In-
deed, in current mouse models, especially the genetically
engineered models, the representation of the mutation
loads found in human tumors is limited. Thus, improved
strategies in the aspect of human/mouse discrepancy
should be identified.
Modeling of the TME
Studying the complex niche of the TME is critical for
understanding key questions related to IO. For example,
the lack of efficacy of adoptively transferred T cells such
as chimeric antigen receptor (CAR) T cells for solid
tumor in either immune active or immune silent tumors.
The IO approaches and the corresponding TME models
are different. Altering the balance in the immunosup-
pressive TME to enhance immune activation could focus
predominantly on experimental models of adaptive im-
mune responses such as the balance between Th2 and
Th1. This may include blockade of CSF1-mediated sus-
tenance of macrophages and IL-4/IL-13-mediated Th2
cell growth [168]. Based on mounting evidence that
CSF1 receptor antagonists improve the efficacy of im-
munotherapy, the combination of anti-CSF1 receptor
antibody with anti-PD-1 antibody and chemotherapy has
been studied in the MMTV-PyMT breast cancer mouse
model. The triple combination led to primary tumor re-
gression and diminished pulmonary metastasis compared
to monotherapy of the agents, or any two of the agents in
combination (Coussens et al. unpublished data).
Another issue in preclinical models is the tissue-
specific regulatory activity displayed by different types
of tumors. In mesothelioma, Th2 cells promote
macrophage pro-tumorigenic programing of tumor
tissue and further inhibit antigen presentation by den-
dritic cells to CD8+ T cells. In squamous cell carcin-
oma, in contrast, B cells and humoral immunity
enhance macrophage pro-tumorigenic programing and
subsequent tumor growth, as well as inhibit antigen
presentation to CD8+ T cells [169, 170]. Therefore, in
squamous cell carcinoma, anti-CD20 or other relevant
inhibitors, such as those targeting Bruton’s Tyrosine
Kinase, could switch the TME from pro-tumorigenic
to anti-tumorigenic.
Surrogate ex vivo models to study CIR
Testing mechanisms of CIR in vivo by adopting animal
models has several limitations for the reasons discussed
above. Surrogate approaches have been described
attempting to utilize tissue reconstructs such as three-
dimensional organoids [171], in vitro three-dimensional
printing [172] and other three-dimensional models [173]
that have been used to assess the role of various compo-
nents of the TME and potential targets for therapy
including stromal matrix and proteins involved in
cell-to-cell interactions by coculturing with lymphocytes
[171, 173–175]. The advantage of these models is their
amenability to stringent control of the tissue compo-
nents assessed within a given experimental context and
may in fact represent ideal grounds to test basic con-
cepts related to migration and activation of immune
cells in different conditions of immune exclusion and
immune suppression. To date, however, limited experi-
ence has been gained in using these models systems to
study the complex and multi-parametric biology of CIR
despite emerging evidence of their utility [176–178]. For
instance, Sherman et al. [178] have analyzed the chemo-
tactic response of NK cells to human stromal-cell derived
factor-1α that permits the simultaneous investigation of
immune cell homing, invasion, and cytotoxic activity.
Take-home messages and challenges in the use of
experimental models
 Mouse models are important to answer mechanistic
questions that are unlikely to be answered by clinical
trials and to validate hypotheses generated from
clinical observations. The choice of mouse model
needs to be selected for the experimental purpose:
 Relevant immune cells and cytokines need to be
considered for the therapy being tested
 If necessary, implantation site should be matched
to cancer tissue of origin (orthotopic vs.
subcutaneous)
 If possible, the genetics of the tumor model
should match the corresponding human genetic
background status that it is supposed to represent
 Best done with immune PDXs or genetically
engineered mouse models
 While humanized mouse models are becoming
more representative, challenges remain:
 Limitations in supporting robust human immune
responses need to be overcome
 Cost remains high (tends to lower throughput)
 There is an unmet need for unlimited HSCs for
reconstitution
 Transplantable cells may not be necessarily
representative of the original tumors
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 Individual models have their own limitations:
 Transgenic models have very low mutation load
and poor intra- and inter-tumor heterogeneity that
may not be representative of any human tumor
 Carcinogen models have high mutational load
and high heterogeneity that may make them
unrealistically immunogenic
 PDX models may become skewed in their biology
by the diverse immune environment encountered
by growing in a different species
 Fragments of PDXs maintain, at least initially,
intra-tumoral immune cells but these are lost
in subsequent passages making them dynamic-
ally unstable
 All immune cells should be analyzed when possible:
 Most of the field is currently CD8+ T cell-focused
 Other cell types are important in effector functions
 APCs, myeloid, B cells, and other rare cells
subtypes remain understudied
Unanswered questions in the use of experimental models
and strategy to address the challenges
 What are the current limitations of humanized PDX
mouse models?
 What approaches can be undertaken towards more
faithful models of human cancer-human myeloid
cells interface?
 How to develop models that better model to
reproduce tumor mutational load?
As described in the previous section, animal and
surrogate tissue modeling system are critical to under-
stand the physiology of innate and adaptive immune
responses. No individual model suffices as it cannot rep-
resent the heterogeneity of cancer tissues from the same
patient and, even more, among patients and distinct can-
cer typologies. In particular, the determinism of CIR can
be dissected starting from basic concepts such as the
dissection of the role of ICD as an initiator of the danger
signal. Only context dependent models will be able to
dissect this question satisfactorily and, therefore, the two
conceptually overlapping working groups will be com-
bined to address the role of ICD and innate immune
activation in the most relevant model system based on a
hypothesis-driven path.
Summary and key questions from entire
workshop
Over the course of the two-day workshop, five working
groups of the SITC Cancer Immune Responsiveness
Table 1 Main unanswered questions identified by each working group
WORKING GROUP Main Questions
I. Germline GENETIC Contributions
TO Cancer Immune Responsiveness
1. Which are the key molecular mechanisms involved in anti-tumor immunity that
might be modulated by germline genetic variants?
2. Are common genetic polymorphisms associated with a differential spontaneous
or treatment-induced anti-tumor immune response?
3. How can we implement the study of host genetic diversity to identify novel
biomarkers of responsiveness or toxicity to cancer immunotherapy?
II. Somatic GENETIC Contributions
TO Cancer Immune Responsiveness
1. Can our knowledge of how cancer-intrinsic features influence the tumor
microenvironment help us optimize immunotherapy combinations?
2. How do we harmonize biomarkers derived from different technologies in
order to specifically tailor IO therapy for a patient and increase the likelihood
of response?
3. Will understanding the role of epigenetic re-programming downstream of
molecular alterations in tumor cells reveal new opportunities to combat cancer
immune-evasion strategies?
III. Transcriptional Changes Related to CIR 1. Can we generate transcriptional signature with high predictive value for a specific
tumor-immune microenvironment?
2. Can transcriptional profiling be developed as a biomarker for the CIR?
3. What technological advances do we need to dissect the tumor-immune
microenvironment in space and time?
IV. Immunogenic Cell Death and
Cancer Immune Responsiveness
1. What are the key molecular events that occur during immunogenic cell death
that prime a robust immune response and promote immunological memory?
2. Which therapeutic strategies will more effectively promote ICD while minimizing
off target inhibition of immune responses?
3. How can detection of immunogenic cell death be routinely incorporated
into clinical trials?
V. Experimental Models of the Immune
Landscape of Cancer
1. What are the current limitations of humanized PDX mouse models?
2. What approaches can be undertaken towards more faithful models of
human cancer-human myeloid cells interface?
3. How to develop models that better model to reproduce tumor mutational load?
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Task Force (CIR), incorporating workshop attendees,
discussed the different determinant of CIR, i.e. the gen-
etic background of the host, somatic alterations related
to the oncogenic process, and environmental modifiers,
and the development of improved in vivo models for
screening therapeutic strategies. Following the work-
shop, each working group identified the most relevant
questions that will help advance the understanding of
CIR (see Table 1). These key questions and scientific
needs will help define priorities for research in tumor
immunology and immunotherapy in order to understand
the cancer biology that orchestrates distinct immune
landscapes. The workshop defined the need to develop
specific working groups to tackle the questions identified
in this occurrence. A follow-up workshop is being orga-
nized by SITC to be held in Houston on September 4–5,
2019 that will bring the various working groups together
for the delineation of the collaborative projects, and
such activities will be the subject of the meeting report.
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